Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma

ConditionsDiffuse Large B Cell Lymphoma (DLBCL)Double Expressor Lymphoma

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-80

SponsorRuijin Hospital

About this trial

This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP (CR-CHOP) regimen in the treatment of BCL2/MYC protein double expressor lymphoma.

Eligibility criteria

Qualifiers

Each potential subject must satisfy all of the following criteria to be enrolled in the study.

Disqualifiers

Any potential subject who meets any of the following criteria will be excluded from participating in the study.

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators

Ruijin Hospital

Lead sponsor

Source ClinicalTrials.gov